WVE

Wave Life Sciences Ltd.

A clinical-stage biotech building a family of RNA medicines through its PRISM platform, which uses chemical tweaks called stereopure chemistry to make drugs that can edit, silence, or splice genetic messages. Its experimental treatments target conditions including obesity, alpha-1 antitrypsin deficiency, and Huntington's disease. Founded in 2012 and first named Ontorii, the company's "Wave" name nods to the wave of RNA innovation, and it manufactures its own medicines at a plant in Lexington, Massachusetts.

CINS: Y95308105ISIN: SG9999014716HealthcareUS1 holder

Ownership Activity Financials Filings

WVE

WVE

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Results of Operations and Financial Condition

Other Events

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Results of Operations and Financial Condition